AOD-9604, despite having gone through Phase II and III clinical trials, has limited long-term post-marketing safety data because the compound did not reach drug approval
B12 IV infusions combine B12 with hydrating fluids and complementary micronutrients, offering near-complete bioavailability and broader physiological support
Whilst B12 injections are well-established NHS treatments for documented deficiency, lipotropic combinations lack robust clinical evidence and are not routinely prescribed within the NHS
Misuse may violate federal, state, or local laws
A patient with poor recovery may need sleep, protein, iron, thyroid, hormone, glucose, or inflammatory markers reviewed
FDA testing found up to 40% of online peptides contained incorrect dosages or undeclared ingredients